Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations
✍ Scribed by Sarah Ducamp; Caroline Kannengiesser; Mohamed Touati; Loïc Garçon; Agnès Guerci-Bresler; Jean François Guichard; Christiane Vermylen; Joaquim Dochir; Hélène A. Poirel; Fanny Fouyssac; Ludovic Mansuy; Geneviève Leroux; Gérard Tertian; Robert Girot; Hermann Heimpel; Thomas Matthes; Neila Talbi; Jean-Charles Deybach; Carole Beaumont; Hervé Puy; Bernard Grandchamp
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 177 KB
- Volume
- 32
- Category
- Article
- ISSN
- 1059-7794
No coin nor oath required. For personal study only.
✦ Synopsis
X-linked Sideroblastic Anemia (XLSA) is the most common genetic form of sideroblastic anemia, a heterogeneous group of disorders characterized by iron deposits in the mitochondria of erythroid precursors. XLSA is due to mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. Thirteen different ALAS2 mutations were identified in 16 out of 29 probands with sideroblastic anemia. One third of the patients were females with a highly skewed X-chromosome inactivation. The identification of seven novel mutations in the ALAS2 gene, six missense mutations, and one deletion in the proximal promoter extends the allelic heterogeneity of XSLA. Most of the missense mutations were predicted to be deleterious, and 10 of them, without any published functional characterization, were expressed in Escherichia coli. ALAS2 activities were assayed in vitro. Five missense mutations resulted in decreased enzymatic activity under standard conditions, and two other mutated proteins had decreased activity when assayed in the absence of exogenous pyridoxal phosphate and increased thermosensitivity. Although most amino acid substitutions result in a clearly decreased enzymatic activity in vitro, a few mutations have a more subtle effect on the protein that is only revealed by in vitro tests under specific conditions.